Biotech | May 27, 2022
Lancet publishes results of Phase 3 programmes of Rinvoq in Ulcerative Colitis
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
The integration and transition of the brands are expected to be completed by June 2022.
Lung cancer is the leading cause of cancer death in the USA, making up almost 25% of all cancer deaths
Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
The groundbreaking SPF technology is specifically designed and formulated to prevent sunburn or sun damage while allowing the passage of sufficient UVB light that our bodies use to naturally produce vitamin D
The centre works with active pharmaceutical ingredients (APIs) and can utilize innovative concepts with model APIs
The acquisition is subject to customary closing conditions and necessary regulatory approvals. The financial terms of the transaction are confidential
The company has posted net loss of Rs. 460.21 crores for the Financial Year ended March 31, 2022.
The AI and technology upgrades allow doctors to choose their medical speciality and even spelling preferences to set their own speech model
The aim is to provide further insights into patients' lives in the effort to deliver better outcomes for people with psoriatic arthritis (PsA)
Subscribe To Our Newsletter & Stay Updated
